Home | ERT

MOVING AHEAD REQUIRES A SURE PATH FORWARD

Trials are inherently risky, and every detail matters. We spot risks before they become problems to help you avoid costly delays through an array of solutions that provide confidence at every turn.

ENHANCE TRIAL OVERSIGHT

Run more efficient trials by unlocking hidden insights
Learn More

enable site optimization

Generate high-quality data by optimizing site selection and performance
Learn More

increase patient engagement

Equip patients with the tools to take control of their health
Learn More

ensure safety and measure efficacy

By driving high-quality data
Learn More

THE ERT EXPERT PLATFORM

The ERT EXPERT^® platform is the underlying proprietary technology that powers all ERT solutions. Improve trial visibility and performance and reduce time-to-market with confidence, agility and acceleration.

Learn More

MINIMIZe RISK AND UNCERTAINTY

We enable the flexibility and adaptability you need to accelerate through hurdles for faster speed to market. Here’s how:

EXPERTS IN COMPLEXITY

Supported 550+ new drug approvals

With decades of experience in applying data and technology solutions to support clinical research, we have technology and scientific expertise to help you succeed at any level of complexity.

60%+

of all FDA-approvals in 2017

ADAPTIVE PROBLEM SOLVING

235k investigative sites supported

Every trial runs into unexpected challenges. With more than 13,000 trials under our belt, we’ve seen most of them before and have the expertise to put your trial back on course.

13K+

Trials supported

ANTICIPATORY OVERSIGHT

25 ready-to-launch analytics tools

We’ll protect the success of your trial before there’s ever an issue, with near real-time access to study, program and enterprise-level performance.

3M+

global patients supported

NEWS & EVENTS

Four Steps to Implementing Risk-based Quality Management

Learn how a Risk-based Quality Management (RBQM) approach to trial management ─ including technology that integrates data from multiple sources for real-time decision making ─ helps sponsors and CROs mitigate clinical trial risks before they become costly problems.

ERT Appoints Industry Veteran to Advance eCOA Strategy

Zaher El-Assi joins Executive Management Team

Why Early Phase Cardiac Safety Assessment Makes Good Business Sense

Learn how determining the cardiac safety profile of your compound by assessing QT during routine Phase I studies enables you to make go/no-go decisions sooner, better prioritize your drug development pipeline, and appropriately resource or refocus programs exhibiting potential cardiac safety issues.

Request A Quote